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Introduction: Superior vena caval obstruction (SVCO) is a not un-
common complication of malignant disease. Treatment may consist of
radiation (RT) to the mediastinum, systemic therapy for chemosensitive
tumors, and supportive measures such as oxygen and steroids. Ad-
vances in interventional radiology have allowed the introduction of
expandable stents into the superior vena cava (SVC), with the theoret-
ical advantage of providing symptom relief within hours, rather than the
days and weeks over which RT exerts its effect. Although small case
series have supported the use of stents in SVCO, there are no random-
ized data.
Methods: We set up a randomized study at Princess Margaret Hospi-
tal, Toronto. Patients were randomized to receive palliative RT to the
mediastinum or immediate stenting of the SVC and then mediastinal
RT within a week. The aim of the study was to compare symptom
response between the two treatment arms. A second study, a prospec-
tive longitudinal study, was also set up to obtain information on
symptom response and outcome regardless of the treatment given.
Results: In a 12-month period, we were unable to accrue any
patients in the randomized study; of the 19 patients approached, 13
have agreed to participate in the longitudinal study.
Conclusions: In this report, we present the problems that we have
encountered with these studies.
Key Words: Superior vena caval obstruction, Radiation, Stent,
Randomized, Symptoms.
(J Thorac Oncol. 2007;2: 514–519)
Superior vena caval obstruction (SVCO) is a not uncom-mon complication of malignant disease, especially lung
cancer. It is evident in 3.8% of lung cancer patients at
diagnosis,1 and it may also develop during the course of the
disease. Other causes of malignant SVCO are lymphoma and
various primary or metastatic malignancies causing acute or
chronic compression of the superior vena cava (SVC). The
treatment of SVCO often includes the use of mediastinal radia-
tion (RT)2,3 or systemic therapy,4,5 particularly in chemosensi-
tive tumors such as small-cell lung cancer or lymphoma. Ste-
roids may be given concurrently with either of these treatments
to reduce any associated edema.6,7 Recent advances in interven-
tional radiology have allowed expandable stents to be inserted
percutaneously into the SVC,8–11 with the theoretical advantage
of providing symptom relief within hours, as opposed to the
days or weeks over which RT usually exerts its effect.
Rowell and Gleeson1 have published an excellent re-
view of the literature regarding the management of this
condition in lung cancer patients. They highlight many of the
deficiencies associated with study in this area: the lack of
well-designed randomized controlled trials, the wide varia-
tion in the data collected, the lack of a standardized scoring
system to measure response, and the lack of a formal system
to record treatment-related morbidity. Chemotherapy and
radiotherapy seem to be effective in relieving SVCO in many
patients, but stent insertion may provide faster relief in a
greater proportion of patients. Evidence from randomized
studies would be very valuable in the management of SVCO
regarding the usefulness and timing of SVC stents.
In this report, we present the details of two studies that
we set up at Princess Margaret Hospital, Toronto, for patients
with malignant SVCO. We highlight the difficulties that we
have encountered with these studies, and we put forward
some suggestions to overcome such difficulties.
MATERIALS AND METHODS
A Randomized Trial Comparing RT with
Stent Insertion and RT in the Treatment Of
Malignant SVCO
The primary objective of this study was to compare the
symptomatic improvement in patients with malignant SVCO
who were randomized to receive palliative mediastinal RT (20
Gy in five fractions) or immediate stent insertion followed the
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next week by RT. The eligibility criteria are listed in Table 1.
Investigations before study entry are detailed in Table 2.
Each patient was issued a diary that included disease-
related symptoms, symptom burden, and quality of life (see
Appendix 1). The diary was to be completed on a daily basis
for the first month, starting on the day of randomization (to be
completed before stent insertion or first fraction of RT), then
weekly for 1 month, and then monthly for 5 months or until
death. The diary asked about certain symptoms: cough, chest
pain, hemoptysis, dysphagia, dyspnea, difficulty lying flat, fa-
tigue, headache or feelings of pressure in the head, and swelling
of the face, neck, or arms. Patients had to rate how much these
symptoms had been bothering them in the last 24 hours. Four
symptoms were identified by the physicians as more specific to
SVCO (dyspnea, headache or feelings of pressure in the head,
difficulty lying flat, and swelling). Each patient was asked to
identify which of these four symptoms was the most trouble-
some; this was classed as his or her index symptom.
The primary endpoint was improvement in the index
symptom (i.e., at least one category better, such as from very
much to moderately), as recorded by the diary, at 4 weeks.
Secondary endpoints were time to onset of palliation, duration of
symptom control, survival, number of days spent in the hospital
between entry to study and 4-week assessment point, cost,
requirements for further treatment, and results of further treat-
ment. Follow-up was an outpatient appointment at 1 month,
substituted by telephone follow-up as necessary. Further data
collection was coordinated by a study nurse via telephone contact.
Stratification was by histology (chemosensitive tumors
versus all other histologies) and by center. Sample size (60
patients in each arm) was planned to detect a 30% difference
in outcome between the two arms ( of 0.05 and  of 0.90).
The calculation assumed a 20% dropout rate.
A Prospective Longitudinal Study of the
Management and Outcome of SVCO
The primary objective of this study was to prospectively
record all patients who presented with SVCO and to document
their symptoms. Eligible patients were those with symptomatic
clinical and radiological diagnosis of SVCO who were deemed
suitable for palliative treatment (mediastinal RT, stent insertion,
or both). They had to have an Eastern Cooperative Oncology
Group performance status of 0 to 3 and to be able to give written
informed consent. There were no specific exclusion criteria, and
no particular investigations were required. Treatment was given
as was considered clinically appropriate. This study protocol had
the approval of our local research ethics board. Patients who
were deemed ineligible for the randomized study or who de-
clined participation in the randomized study were eligible for the
prospective study.
Patient data at baseline were collected on a standardized
database form, and follow-up information was collected using
the same diary cards as described in the randomized study.
The primary endpoint of the study was improvement in
the index symptom, and secondary endpoints were time to onset
of palliation, duration of symptom control, and survival. Fol-
low-up appointments were the same as for the randomized study.
RESULTS
The studies were opened at our comprehensive cancer
center in October 2001. At the time of this analysis (October
2005), 19 patients have been approached about the studies.
No patient was successfully accrued for the randomized
trial within the 12-month study period, and the study was thus
closed. The reasons for nonaccrual are presented in Table 3.
TABLE 1. Eligibility Criteria for the Randomized Trial Comparing
Radiation Therapy with Stent Insertion and Radiation in the
Treatment of Malignant Superior Vena Caval Obstruction
Inclusion Criteria Exclusion Criteria
Symptomatic clinical and radiological
diagnosis of superior vena caval
obstruction




Deemed appropriate for palliative
radiation therapy
Life expectancy greater than 6 weeks
Eastern cooperative oncology group
performance status 3
Technically suitable for a superior vena
caval stent
Ability to lie supine for 30 minutes
Informed consent
TABLE 2. Investigations to be Performed Before Entry into
Randomized Study
Investigations Before Study Entry Reason for Investigation
Chest x-ray To determine extent of disease
Computed tomography of thorax
with contrast enhancement
To determine extent of disease
Computed tomography of head
with contrast enhancement
To determine presence of brain
metastases (scanned at the
discretion of the radiologist before
stent insertion and
anticoagulation)
CBC, INR, PTT To be done before stent insertion, as
is usual clinical practice
All studies to be performed within 4 weeks of entry into study
CBC, complete blood count; INR, international normalized ratio; PTT, partial
thromboplastin time.




Clinical decision for radiotherapy 3
Unsuitable for stent; technically not possible or advisable 3
Clinical decision for stent (previous radiotherapy to
mediastinum)
1
Unsuitable for stent insertion or radiotherapy 1
Patient refusal of stent 1
Ethics approval not complete at one hospital site (MSH) 1
MSH, Mount Sinai Hospital.
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In three patients, it was deemed clinically appropriate to offer
RT rather than entry into the randomized study. Two of these
patients had extensive disease (nodal disease, pleural effu-
sions, lung metastases, bone metastases, lymphangitis), and it
was felt that their symptoms would be best palliated with RT.
The third patient had symptoms that were attributable more to
airway obstruction than to SVCO. In three patients it was not
considered technically possible or advisable to proceed with
stent insertion. For example, one patient had disease extend-
ing into the right atrium; another patient was only mildly
symptomatic, and the potential risks of the stenting procedure
were felt to outweigh the possible benefits. An SVC stent was
inserted in one patient who had had previous RT to the
mediastinum, and one man with extensive pleural effusion
and poor performance status died before receiving treatment.
One patient declined study entry, not wishing to be consid-
ered for stent insertion.
Thirteen patients agreed to participate in the prospec-
tive longitudinal study. The reasons for nonaccrual are pre-
sented in Table 4. Of the 13 patients accrued, two were deemed
not eligible, and we have follow-up data for five patients. Two
patients did not complete the diary card, and two patients could
not be contacted despite multiple attempts at doing so by
telephone and mail. Two patients died during the follow-up, and
their diaries were not returned by their relatives.
The baseline database form was completed for 18/19
patients. Patient characteristics are shown in Table 5. The
median age was 62 years (range 49–82). There were six men
(6/19; 33%) and 12 women (12/19; 67%). Median Eastern
Cooperative Oncology Group performance status was 2. The
lungs were the most common primary site (12 non-small cell
lung cancer; 1 small-cell lung cancer). Three patients had
breast cancer, and two patients had unknown primary sites.
Nodal disease caused the SVCO in the majority of cases (11/18;
61%). Presenting symptoms were dyspnea (17), fatigue (12),
swelling (13), cough (12), difficulty lying flat (9), chest pain (8),
difficulty swallowing (3), hemoptysis (5), headache (4), and
syncope (2). Seventeen patients described three or more symp-
toms, up to a maximum of eight. Eleven patients identified
dyspnea as their index symptom; four identified swelling of their
face, neck, and arms; and three identified difficulty lying flat.
Four of the 12 patients were on steroids at the time of evaluation
of SVCO, and two patients were prescribed steroids at the time
of the consultation. There was no difference in baseline charac-
teristics between all patients and those successfully accrued for
the prospective longitudinal study. To date, 15 of the 18 patients
have died, with a median survival from time of SVCO diagnosis
of 6 months.
Of the 19 patients approached (Figure 1), 17 received
RT. All but one completed a course of 20 Gy in five daily
TABLE 5. Patient Characteristics











Non-small cell lung cancer 12




Shortness of breath 11
Difficulty lying flat 4
Swelling of face, neck or arms 3
FIGURE 1. Flow diagram of patients approached re-entry
into studies.





Patient refusal to complete diary 2
Poor understanding of disease/poor historian 1
Awaiting investigation? Malignant superior vena caval
obstruction
1
Died before receiving any treatment 1
Symptoms more of airway obstruction 1
Patient was deemed asymptomatic after study accrual 1
Patient was an inpatient and too ill to continue with study 1
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fractions, using anterior and posterior fields prescribed at
midplane. Two patients, one with endobronchial disease and
bulky mediastinal disease from previous breast cancer, and
one patient with extensive non-small cell lung cancer disease
in the locoregional area, were treated to 30 Gy in 10 fractions.
Because of the lack of success in enrolling patients into
the randomized controlled trial, and concerns that the accrual
goal will never be reached, that trial was closed in 2003. The
prospective longitudinal study is still open.
DISCUSSION
We practice in the era of evidence-based medicine.
Rowell and Gleeson1 highlight in their systematic review that
some aspects of the management of SVCO do not have a
good evidence base. In particular, there is a lack of random-
ized studies: an electronic literature search from 1966 to 2001
identified only three randomized trials, which looked at the
use of chemotherapy and radiotherapy.5,12,13 There were no
randomized studies of the use of SVC stents, nor did any
studies, either randomized or not, explore the effectiveness of
steroids in this patient group. Ninety-eight nonrandomized
studies were identified, but methodological issues were
raised. The studies often examined a heterogeneous patient
group, with diseases other than lung cancer, and performance
status was recorded in few. There was no consistent endpoint
as to the improvement in SVCO, and only two studies
actually used any sort of scoring system. There was a lack of
data regarding treatment-related morbidity, although the stud-
ies of SVC stents were somewhat better in this regard.
The evidence for the use of SVC stents comes from
small case series.8–11 Patients in the study by Lanciego10 were
all treatment naı¨ve, whereas those in the study by Oudkerk8
had failed previous chemotherapy and/or radiotherapy.
Symptom response was achieved in 76% to 100% of patients,
with subsequent relapses in fewer than 10%. One study
compared stent insertion in a subgroup of 26 patients against
a retrospective group of 25 patients treated with RT.14 The
authors found that stent insertion provided significantly faster
relief of symptoms as measured by a symptom score (p 
0.001). The other comparative study, by Tanigawa et al.,15
demonstrates that overall symptom improvement and survival
were similar between the stent (n  23) and RT groups (n 
10). The survival of patients with intraluminal tumors was
significantly worse than those with extrinsic compression
(44.9 days versus 198.6 days; p  0.05).
We had noted that there was a lack of phase III random-
ized studies to support the use of SVC stents, and we designed
a study to address this issue. Unfortunately, this study has now
closed because of a lack of accrual, having been open for 12
months. Despite the enthusiasm of both the RT oncologists and
the interventional radiologists involved, several methodological
and logistical problems resulted in poor accrual.
The detection of patients who were potentially suitable
for participation in either of the studies was the first hurdle.
Although SVCO is not an uncommon clinical problem, patients
may be referred to, or present to, RT or medical oncology.
Princess Margaret Hospital is a large cancer center with, at that
time, four RT oncologists specializing in thoracic malignancies
and four others seeing lung cancer patients as part of the
palliative RT oncology program. We wanted to accrue as many
patients as possible over a reasonable time period; therefore, we
did not limit study entry to only those with a lung primaries. We
advertised the study by intrahospital e-mail, presentations, and
posters in clinic areas because we wanted to approach patients
for entry to the study as soon as they had been found to have
symptomatic SVCO. SVCO was identified in some patients at
the time of a routine CT chest, but to be eligible for study, they
had to have associated symptoms. Despite our efforts at adver-
tising the study, there may have been patients with SVCO seen
and treated by oncologists not involved in the study.
Accrual of patients for studies can often be challeng-
ing.16 SVCO usually occurs in patients who have locally
advanced or metastatic disease, and the treatment intent is
therefore palliative. It is well known that palliative patients
present their own challenges for study participation17: they
are a heterogeneous group, perhaps older, with limited life
expectancy, poor performance status, or complicating comor-
bidities. Of the patients in the study by Ling et al.,17 17% had
lung primaries. SVCO has a variety of causes (primary or
metastatic disease, which can be of various histology) and
can occur in treatment-naı¨ve or previously irradiated patients.
Our inclusion criteria were broad, to try to encompass as
many patients as possible. The only exclusion criterion was
previous RT to the mediastinum, but we still found that
several patients had to be excluded because of previous RT,
chemosensitive disease, or disease that was not technically
suitable for stenting (i.e., either too close to the right atrium
or too extensive). One patient refused study entry because of
unwillingness to consider stent insertion, and one patient was
too unwell to be considered for either RT or stent insertion.
Many patients were not eligible for the randomized study
because it had been determined that they would be best
palliated with RT. In some, the shortness of breath was
caused in part by SVCO, but also by airway obstruction,
nodal disease, pleural effusions, lung metastases, and lym-
phangitis. The concept of randomization is difficult to explain
to patients,18 particularly in a study such as this one, where
the two treatment arms are perceived to be very different.
Patients often are nervous at the idea that the doctors do not
know which treatment is best for them, and they would
prefer, therefore, to have the standard treatment. Our inter-
ventional radiologists were excellent in their availability to
see patients, but some patients still refused participation in
the study because they perceived there would be a delay in
the start of their treatment. The management of SVCO has
been the subject of critical review, and many authorities now
believe that emergency treatment is not required in most
cases,19,20 especially in the presence of adequate collaterals.
Nevertheless, some doctors still feel that SVCO is an onco-
logical emergency, and patients sometimes do present late
with marked symptoms, with treatment initiated without
delay. Toronto is a multicultural city, and as such, a language
barrier may be present. The diary card was only available in
English, but it could be completed with the aid of a translator
or family member as needed. Even to those whose first
language was English, the diary card sometimes seemed
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daunting. Interestingly, the diary card was a modification of
that used in the Canadian palliative RT study, and no such
problems had been encountered during that study.21
SVC stents are expensive. Interest in the studies had
been shown by another large cancer center in Toronto, but
they were unable to participate because of an inability to
secure funding. SVCO is a relatively uncommon condition,
and a multicenter study may have been able to accrue more
successfully, although coordination among centers is vital.
There are logistical problems associated with the organi-
zation and maintenance of such a multidisciplinary study. We
were fortunate to have the services of a research assistant who
was able to coordinate appointments and organize follow-up,
either in the clinic or by telephone. Previous work within the
palliative RT oncology program has shown that telephone fol-
low-up of patients treated with palliative RT achieves similar
quality and completeness of data collection as does clinic fol-
low-up, but a combined approach may be the most successful.22
We felt that symptom response was the most important
endpoint for the study. We did not routinely perform posttreat-
ment imaging; that was left to the discretion of the investigator.
We did try to have some form of reproducible assessment of
symptoms in the form of the diary card, which also included
some general questions regarding quality of life. There were
defined criteria for response to treatment. A potential criticism of
our study was that we only recorded performance status and
steroid use at presentation. Also, the routine use of anticoagu-
lation post-SVC stent insertion is not evidence based, but it is the
standard clinical practice in our institution.
At the time of design of the randomized protocol, we
were aware that difficulties might be encountered, and we
devised the prospective longitudinal study to run concurrently
to try to capture as much information as possible about
patients with symptomatic SVCO. This study is still open to
accrual, although patient identification and the urgency of
treatment present continued challenges.
CONCLUSION
Although data are available from small series on the use
of SVC stents to relieve symptoms of SVCO, there are no
randomized trial data to support their use. We have tried
unsuccessfully to conduct a clinically relevant and pragmatic
randomized study to obtain such data. Detection of suitable
patients for consideration of the study was hard because of
the referral patterns of patients with SVCO and because their
symptoms may be multifactorial. Despite broad eligibility
criteria, many patients were not suitable for the study. Pa-
tients may present late with marked symptoms and require
urgent treatment or be unsuitable for stent insertion. Stents
are expensive equipment, and lack of funding contributed to
the lack of participating centers and, hence, to the unsuccess-
ful completion of the trial.
We question whether it is possible to obtain random-
ized data in this palliative patient group, and we encourage
the collection of symptom data in phase II studies.
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APPENDIX 1
Diary Card
PLEASE COMPLETE THE 
SYMPTOM DIARY AS PER 
INSTRUCTIONS





Day 1 2 3 4 5 6 7
Shortness of breath
Difficulty in lying flat 
Swelling of face, neck or arms 









0 = Not at all
1 = A Little
2 = Moderately
3 = Very much
On day 7, please answer the following questions as well:
How bad are your symptoms from cancer?
I have none As bad as they could be
How much has your illness affected your ability to carry out normal activities?
Not at all So much that I can do 
nothing for myself
How would you rate the quality of your life today?
Very high Very low
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